{"id":8674,"date":"2016-12-06T00:00:00","date_gmt":"2016-12-06T00:00:00","guid":{"rendered":"https:\/\/mcpinvest.com\/it\/https-www-mcpinvest-lu-mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/"},"modified":"2022-04-04T08:18:27","modified_gmt":"2022-04-04T08:18:27","slug":"mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa","status":"publish","type":"post","link":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/","title":{"rendered":"MCP acquisisce il controllo di Mipharm S.p.A."},"content":{"rendered":"<style type=\"text\/css\"><\/style>\n<section class=\"kc-elm kc-css-3660892 kc_row\">\n<div class=\"kc-row-container  kc-container\">\n<div class=\"kc-wrap-columns\">\n<div class=\"kc-elm kc-css-1500044 kc_col-sm-12 kc_column kc_col-sm-12\">\n<div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-2141568 kc_text_block\">\n<h1><strong>MANDARIN CAPITAL PARTNERS ACQUISISCE IL CONTROLLO DI MIPHARM SPA<\/strong><\/h1>\n<h4>Milano &#8211; 6 Dicembre 2016 &#8211; <strong>Mandarin Capital Partners II (MCP II)<\/strong> ha completato con successo l\u2019acquisto di una quota di maggioranza nel capitale sociale di <strong>Mipharm Spa<\/strong>, azienda Italiana leader nel Contract Manufacturing Organization (\u201cCMO\u201d) attiva nella produzione e confezionamento di un\u2019ampia gamma di farmaci in conto terzi (Finished Dosage Formulations) e nella fornitura di servizi di ricerca e sviluppo di nuovi prodotti e studi clinici basati sia sulle richieste dei clienti sia sull\u2019attivit\u00e0 di R&amp;D interna.<\/h4>\n<h4>L\u2019investimento iniziale di MCP II ammonta a \u20ac 16.4 milioni, con l\u2019obiettivo di incrementare l\u2019investimento totale con future acquisizioni di Target selezionati. Cassiopea Partners (advisor finanziario del compratore), Euteam (Societ\u00e0 di propriet\u00e0 di Maurizio Silvestri &#8211; ex CEO di Euticals) e alcuni dei Managers di Mipharm hanno reinvestito con una quota di minoranza nella societ\u00e0.<\/h4>\n<h4>L\u2019attuale CEO, il Dott. <strong>Pierangelo Costa<\/strong>, continuer\u00e0 a gestire la societ\u00e0. Nell\u2019esercizio 2015, Mipharm ha realizzato ricavi per \u20ac 37.9 milioni, con circa 45 clienti (principali player nel mercato pharma, produttori globali di farmaci generici, altre societ\u00e0 farmaceutiche) in 30 nazioni (e.g. nell\u2019esercizio 2015 l\u2019Export ammontava a circa il 65% del fatturato).<\/h4>\n<h4>L\u2019obiettivo dell\u2019investimento \u00e8 supportare la crescita internazionale della Societ\u00e0, facendo leva sul network di MCP II nei mercati Europei e Asiatici.<\/h4>\n<h4><strong>Cassiopea Partners<\/strong> e gli avvocati dello studio legale <strong>R&amp;P Legal<\/strong> di Milano hanno agito rispettivamente come advisor finanziario e legale per MCP II; <strong>BPM<\/strong> e <strong>BPER<\/strong> hanno agito in qualit\u00e0 di banche finanziatrici dell\u2019operazione. I venditori sono stati assistiti da <strong>Rothschild <\/strong>come financial advisor e dai legali dello studio legale <strong>Bonelli Erede Pappalardo<\/strong> di Milano per i profili legali.<\/h4>\n<h4>Mandarin \u00e8 stata assistita nel processo di due diligence da <strong>Ernst &amp; Young<\/strong> (profili contabili e fiscali), <strong>R&amp;P Legal<\/strong> (profili legali), <strong>Goetz Partners<\/strong> (analisi di business) e <strong>Tauw<\/strong> (analisi ambientale).<\/h4>\n<hr>\n<h4>Milan \u2013 6th December 2016&nbsp;\u2013&nbsp;<strong>Mandarin Capital Partners II (MCP II) &nbsp;<\/strong>has successfully acquired a majority stake in the share capital of&nbsp;<strong>Mipharm Spa,&nbsp;<\/strong>an Italian leading Contract Manufacturing Organization (\u201cCMO\u201d) engaged in the manufacturing and packaging of a wide range of Finished Dosage Formulations (\u201cFDFs\u201d). The Group also provides product development services and clinical studies based on customer requirements and\/or in house R&amp;D.<\/h4>\n<h4>MCP II total initial investment amounts to \u20ac 16.4 million, with the goal to increase the total investment with acquisitions of selected targets. Cassiopea Partners (Buyer\u2019s financial advisor), Euteam (company owned by Mr. Maurizio Silvestri \u2013 ex CEO of Euticals) and some of Mipharm\u2019s Managers invested alongside MCP II.<\/h4>\n<h4>Current CEO Mr.&nbsp;<strong>Pierangelo Costa<\/strong>&nbsp;will continue to manage the company<strong>.<\/strong>&nbsp;Mipharm has posted sales of around \u20ac 37.9 m in 2015, with approx. 45 clients (Big Pharma, Global Generic companies, other pharmaceutical companies) located in 30 countries (i.e. in 2015 Exports account for about 65% of Revenues).<\/h4>\n<h4>The investment is aimed at supporting international growth of the Company, leveraging on MCP II\u2019s network and business development channels in the European and Asian markets.<\/h4>\n<h4><strong>Cassiopea Partners<\/strong>&nbsp;and the lawyers of<strong>&nbsp;R&amp;P Legal<\/strong>&nbsp;of Milan acted respectively as financial and legal advisor for MCP II;&nbsp;<strong>BPM<\/strong>&nbsp;and&nbsp;<strong>BPE<\/strong>R acted as financing banks providing the acquisition and M&amp;A lines. The seller was supported by&nbsp;<strong>Rothschild<\/strong>&nbsp;as financial advisor and by the lawyers of<strong>&nbsp;Bonelli Erede Pappalardo<\/strong>&nbsp;as legal advisor.<\/h4>\n<h4>The due diligence process was conducted by&nbsp;<strong>Ernst &amp; Young<\/strong>&nbsp;(financial and tax areas),&nbsp;<strong>R&amp;P Legal<\/strong>&nbsp;(legal area),&nbsp;<strong>Goetz Partners<\/strong>&nbsp;(business) and&nbsp;<strong>Tauw<\/strong>&nbsp;(Environmental).<\/h4>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Milano, 6 Dicembre 2016 &#8211; Mandarin Capital Partners II (MCP II) ha completato con successo l\u2019acquisto di una quota di maggioranza nel capitale sociale di Mipharm Spa.<\/p>\n","protected":false},"author":2,"featured_media":8675,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[88],"tags":[],"class_list":["post-8674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mcp-ii"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner\" \/>\n<meta property=\"og:description\" content=\"Milano, 6 Dicembre 2016 - Mandarin Capital Partners II (MCP II) ha completato con successo l\u2019acquisto di una quota di maggioranza nel capitale sociale di Mipharm Spa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/\" \/>\n<meta property=\"og:site_name\" content=\"MCP - Mindful Capital Partner\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-06T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-04T08:18:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redazione MCP\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redazione MCP\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/\"},\"author\":{\"name\":\"Redazione MCP\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#\\\/schema\\\/person\\\/3dfbd247811b40167739a5a459f829db\"},\"headline\":\"MCP acquisisce il controllo di Mipharm S.p.A.\",\"datePublished\":\"2016-12-06T00:00:00+00:00\",\"dateModified\":\"2022-04-04T08:18:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/\"},\"wordCount\":611,\"publisher\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1\",\"articleSection\":[\"MCP II\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/\",\"url\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/\",\"name\":\"MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1\",\"datePublished\":\"2016-12-06T00:00:00+00:00\",\"dateModified\":\"2022-04-04T08:18:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MCP acquisisce il controllo di Mipharm S.p.A.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/\",\"name\":\"MCP - Mindful Capital Partner\",\"description\":\"MCP - Mindful Capital Partner\",\"publisher\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#organization\",\"name\":\"MCP - Mindful Capital Partner\",\"url\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/MCP_Standard_StandardNero_RGB.png\",\"contentUrl\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/MCP_Standard_StandardNero_RGB.png\",\"width\":8000,\"height\":3525,\"caption\":\"MCP - Mindful Capital Partner\"},\"image\":{\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/mindful-capital-partners\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mcpinvest.com\\\/it\\\/#\\\/schema\\\/person\\\/3dfbd247811b40167739a5a459f829db\",\"name\":\"Redazione MCP\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g\",\"caption\":\"Redazione MCP\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/","og_locale":"it_IT","og_type":"article","og_title":"MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner","og_description":"Milano, 6 Dicembre 2016 - Mandarin Capital Partners II (MCP II) ha completato con successo l\u2019acquisto di una quota di maggioranza nel capitale sociale di Mipharm Spa.","og_url":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/","og_site_name":"MCP - Mindful Capital Partner","article_published_time":"2016-12-06T00:00:00+00:00","article_modified_time":"2022-04-04T08:18:27+00:00","og_image":[{"width":1000,"height":1000,"url":"https:\/\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg","type":"image\/jpeg"}],"author":"Redazione MCP","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Redazione MCP","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#article","isPartOf":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/"},"author":{"name":"Redazione MCP","@id":"https:\/\/mcpinvest.com\/it\/#\/schema\/person\/3dfbd247811b40167739a5a459f829db"},"headline":"MCP acquisisce il controllo di Mipharm S.p.A.","datePublished":"2016-12-06T00:00:00+00:00","dateModified":"2022-04-04T08:18:27+00:00","mainEntityOfPage":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/"},"wordCount":611,"publisher":{"@id":"https:\/\/mcpinvest.com\/it\/#organization"},"image":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1","articleSection":["MCP II"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/","url":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/","name":"MCP acquisisce il controllo di Mipharm S.p.A. - MCP - Mindful Capital Partner","isPartOf":{"@id":"https:\/\/mcpinvest.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#primaryimage"},"image":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1","datePublished":"2016-12-06T00:00:00+00:00","dateModified":"2022-04-04T08:18:27+00:00","breadcrumb":{"@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#primaryimage","url":"https:\/\/i0.wp.com\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1","contentUrl":"https:\/\/i0.wp.com\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/mcpinvest.com\/it\/mandarin-capital-partners-acquisisce-il-controllo-di-mipharm-spa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mcpinvest.com\/it\/"},{"@type":"ListItem","position":2,"name":"MCP acquisisce il controllo di Mipharm S.p.A."}]},{"@type":"WebSite","@id":"https:\/\/mcpinvest.com\/it\/#website","url":"https:\/\/mcpinvest.com\/it\/","name":"MCP - Mindful Capital Partner","description":"MCP - Mindful Capital Partner","publisher":{"@id":"https:\/\/mcpinvest.com\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mcpinvest.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/mcpinvest.com\/it\/#organization","name":"MCP - Mindful Capital Partner","url":"https:\/\/mcpinvest.com\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/mcpinvest.com\/it\/#\/schema\/logo\/image\/","url":"https:\/\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/02\/MCP_Standard_StandardNero_RGB.png","contentUrl":"https:\/\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/02\/MCP_Standard_StandardNero_RGB.png","width":8000,"height":3525,"caption":"MCP - Mindful Capital Partner"},"image":{"@id":"https:\/\/mcpinvest.com\/it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/mindful-capital-partners\/"]},{"@type":"Person","@id":"https:\/\/mcpinvest.com\/it\/#\/schema\/person\/3dfbd247811b40167739a5a459f829db","name":"Redazione MCP","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f752c8ae878c291c45e2c7fc5bd96fed1fe52cdb0130c938ab9017def76b791?s=96&d=mm&r=g","caption":"Redazione MCP"}}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/mcpinvest.com\/it\/wp-content\/uploads\/2022\/03\/Mipharm_Prodotti3-e1593958905986.jpg?fit=1000%2C1000&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/posts\/8674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/comments?post=8674"}],"version-history":[{"count":1,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/posts\/8674\/revisions"}],"predecessor-version":[{"id":8893,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/posts\/8674\/revisions\/8893"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/media\/8675"}],"wp:attachment":[{"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/media?parent=8674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/categories?post=8674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mcpinvest.com\/it\/wp-json\/wp\/v2\/tags?post=8674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}